Improving medication use in residential care: insights of frailty and brain vital signs
About two-thirds of older adults (+65 years of age) who take 5+ medicines experience drug-related negative events (falls, reduced brain function, syndromes). Choosing the right medicines to treat someone’s unique set of health needs is complex, and requires thinking about many factors. Too much or not enough medicine can cause harm to patients, especially older adults living with frailty.
About this project:
Solutions that help healthcare professionals prescribe the right medicines are currently very limited, but emerging research is supportive of new ways to monitor frailty and brain function. Our project uniquely brings together leading researchers, academics, and industry partners in pharmacy and ageing fields to better understand how medicine use relates to frailty and health outcomes. New tools that measure health status in ways that are not dependent on medical opinion are available. First, we will study how medicine use relates to degree of frailty (Frailty Index). Second, we will study how medicine use relates to health outcomes (brain vital signs and other health assessments). As part of our project, we will gather essential data to learn about how these outcomes differ between sexes, if certain medicines and combinations have lower risks, and what makes it easier and/or more difficult for older adults to manage their medicines. If successful, our project will represent the first steps to providing evidence that prescribing and/or deprescribing practices in older adults can be informed by frailty assessments
Project Team:
Principal Investigator:
Xiaowei Song, PhD, MSCS, Fraser Health
Co-Investigators:
Ryan D’Arcy, PhD, Fraser Health
Knowledge User:
Rowena Rizzotti, MBA, Lark Group
Collaborators:
Barbara De Angelis, RPh, BScPhm, ACRP, BCGP, Rexall Pharmacies
Jackie Macli-ing, MSN, BSN, Laurel Place
Linda Fernholm, Laurel Place
HQP:
Chelsea Stunden, MPH, BSc, Health & Technology Districty
Andrew McDonald, MD(c), BSc, University of British Columbia
Fabio Bollinger, BASc, Simon Fraser University
Lukas Grajuaskas, MSc, Simon Fraser University
Tony (Er Dong) Zhang, PharmD, University of British Columbia
Partners:
Laurel Place
Lark Group
Rexall Pharmacies
Fraser Health
Project Contact: Dr. Xiaowei Song — xiaowei.song@fraserhealth.ca
CAT2017-25
Keywords: aging; cognitive decline; polypharmacy; frailty assessment; neurotechnology; Brain Vital Signs